No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.
www.essexbio.comNo one on the platform currently holds 1061.HK.
No tracked institution reports a position in 1061.HK as of their last filing.
No one on the platform has traded 1061.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.3% | 15.9% | 20.0% | — | — | — |
| Rev. Growth % | 8.6% | 13.1% | ||||
| Profit Margin % | 17.5% | 18.1% | 19.2% | |||
| Free Cash Flow Margin % | 7.3% | 11.3% | 8.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.9B | +11.4% | $0.57 | $0.57–$0.57 | — | 1 |
| 2027 | $2.1B | +13.8% | $0.62 | $0.62–$0.62 | — | 1 |
| 2028 | $2.5B | +16.2% | $0.74 | $0.74–$0.74 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.91% |
| $1.4B |
| — |
| 2348.HKDawnrays Pharmaceutical (Holdings) Limited | $0.98 | +0.51% | $1.5B | — |
| 2487.HKCutia Therapeutics | $1.40 | +2.56% | $509M | — |
Source: Financial Modeling Prep · peers by sector/industry